|
Mir A. Imran (born 1956, Hyderabad, India), is an Indian entrepreneur and venture capitalist. Imran has formed 19 companies since the early 80s and holds over 140 patents. Born and raised in India, the son of a doctor, Imran moved to New Jersey in 1973 to attend Rutgers University where he studied both electrical and biomedical engineering. He received his B.S. in electrical engineering and his M.S. in biomedical engineering and spent three years as a Research Specialist before deciding to leave and work on the first implantable cardioverter-defibrillator with Intec Systems, which was acquired by Eli Lilly, spun out to form Guidant, and acquired by Boston Scientific in 2006 for $27.5B Imran is recognized for his history as a scientist, inventor, entrepreneur and investor of medical technology companies. He is the founder and Chairman of InCube Labs, LLC, a research laboratory and business incubator for medical and technology companies. Through InCube Labs, and prior to its establishment, he has founded numerous medical and high technology companies. Imran currently serves as a Director for a number of life science companies ==Business== Imran joined Intec Systems in 1980 and developed IP key to the development of the automatic implantable defibrillator, a device that has saved hundreds of thousands of lives, and has become a standard of care in cardiology. In 1992, Mr. Imran invented a cooled RF ablation catheter for the treatment of ventricular arrhythmias. This invention became the initial product of Cardiac Pathways, and is now widely used by cardiac electro-physiologists. In 1995, he developed a low-pressure balloon and aspirator system for use in catheter based interventions. Mr. Imran was the first to articulate the concept of embolic protection during high-risk interventions. Mr. Imran’s device became the primary innovation for Percusurge, which was acquired by Medtronic in December 2000. In the medical field Imran's interest is to develop medical devices that blur the distinction between organic and synthetic and advance patient treatment options. Imran’s current research interests include tissue engineering, gastroenterology, nephrology, neurology, orthopedics, congestive heart failure and artificial organs. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Mir Imran」の詳細全文を読む スポンサード リンク
|